New York (March 22nd, 2013) - Titan Pharmaceuticals Inc. (OTCQB: TTNP) announced that the majority of Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) members recognized the favorable benefit-risk profile of Probuphine® and voted for approval (10 positive votes, 4 negative votes and 1 abstention).
Probuphine® is a long-acting, subdermal implant formulation of buprenorphine for the maintenance treatment of adult patients with opioid dependence. Titan submitted a New Drug Application (NDA) for Probuphine on October 29, 2012.
"We are pleased the Committee recognized the favorable benefit-risk profile of Probuphine and voted in strong favor of its approval," said Kate Glassman-Beebe, Ph.D., executive vice president and chief development officer of Titan.
Find out more on TTNP
AMR Corporation (OTCQB: AAMRQ)subsidiary American Airlines has decided to equip all of its A320 Family fleet with Airbus' innovative Runway Overrun Prevention System (ROPS) technology.
This onboard cockpit technology, which Airbus has pioneered independently over several years, increases pilots' situational awareness during landing, reduces exposure to runway excursion risk, and if necessary, provides active protection.
"ROPS is the result of years of continuing research by Airbus," said YannickMalinge, Airbus' Senior Vice President and Chief Product Safety Officer. "Its selection by American Airlines for its A320 Family fleet underscores the value and significant contribution that ROPS brings to aviation safety. Airbus is proud to be on the leading edge of this technology for our industry – where safety is the universal priority."
Read the trend analysis report to find out what the market could have in store for AAMRQ here:
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit: www.wallstreetreport.net/disclaimer-2/
WALL STREET REPORT
Leave a comment...